, Volume 76, Issue 16, pp 1559–1566 | Cite as

Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia

  • Yvette N. LambEmail author
  • Gillian M. Keating
Adis Drug Evaluation


A 3-monthly formulation of intramuscular paliperidone palmitate (3-monthly paliperidone palmitate) has recently been approved for the maintenance treatment of schizophrenia in adult patients in the EU (Trevicta®), following earlier approval in the USA (Invega Trinza®). This narrative review discusses the clinical use of 3-monthly paliperidone palmitate in the maintenance treatment of schizophrenia in adult patients and summarizes its pharmacological properties. The efficacy of the 3-monthly paliperidone palmitate formulation as a maintenance treatment for schizophrenia has been demonstrated in well designed, phase III trials. Three-monthly paliperidone palmitate was more effective than placebo in delaying time to relapse and reducing relapse rates, and was noninferior to 1-monthly paliperidone palmitate in the proportion of patients that remained relapse-free. The 3-monthly formulation was also more effective than placebo in controlling the symptoms of schizophrenia, whilst not differing significantly from the 1-monthly formulation in terms of symptomatic control. Three-monthly paliperidone palmitate was generally well tolerated in clinical trials, with a tolerability profile consistent with that of the 1-monthly formulation. In conclusion, 3-monthly paliperidone palmitate is a useful treatment option for adult patients with schizophrenia who are adequately treated with the 1-monthly formulation, particularly for those who would prefer, or may benefit from, longer dosing intervals.


Schizophrenia Placebo Recipient Paliperidone Paliperidone Palmitate Noninferiority Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



During the peer review process, the manufacturer of the paliperidone palmitate 3-monthly formulation was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Yvette Lamb and Gillian Keating are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.


  1. 1.
    Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv. 2004;55(9):997–1005.CrossRefPubMedGoogle Scholar
  2. 2.
    Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adher. 2013;7:1171–80.CrossRefGoogle Scholar
  3. 3.
    Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255–64.CrossRefPubMedGoogle Scholar
  4. 4.
    Daghistani N, Rey JA. Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent. P T. 2016;41(4):222–7.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Lee LHN, Choi C, Collier AC, et al. The pharmacokinetics of second-generation long-acting injectable antipsychotics: limitations of monograph values. CNS Drugs. 2015;29(12):975–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27(8):637–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs. 2010;24(3):227–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Ravenstijn P, Remmerie B, Eng C, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330–9.CrossRefPubMedGoogle Scholar
  9. 9.
    European Medicines Agency. Trevicta (paliperidone palmitate) prolonged release suspension for injection: EU summary of product characteristics. 2016. Accessed 14 Sep 2016.
  10. 10.
    Janssen Pharmaceuticals Inc. Invega Trinza® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use: US prescribing information. 2016. Accessed 14 Sep 2016.
  11. 11.
    Gopal S, Vermeulen A, Nandy P, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin. 2015;31(11):2043–54.CrossRefPubMedGoogle Scholar
  12. 12.
    Nasrallah HA. Atypical antipsychotic-induced metabolite side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects [abstract no. P.1.053]. Eur Neuropsychopharmacol. 2005;15(Suppl. 3):S386.Google Scholar
  14. 14.
    Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163(3):396–401.CrossRefPubMedGoogle Scholar
  15. 15.
    Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7):1–14.CrossRefGoogle Scholar
  16. 16.
    Samtani MN, Rossenu S, Vermeulen A, et al. Paliperidone palmitate 3-month dosing in special patient populations and derivation of secondary pharmacokinetic parameters based on simulations. Biol Psychiatry. 2016;79(9 Suppl 1):353S.Google Scholar
  17. 17.
    Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769–79.CrossRefPubMedGoogle Scholar
  18. 18.
    Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Mathews M, Nuamah I, Savitz A, et al. Comparison of 3-monthly versus 1-monthly paliperidone palmitate for time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia. Biol Psychiatry. 2016;79(9 Suppl 1):352S–3S.Google Scholar
  20. 20.
    Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.CrossRefPubMedGoogle Scholar
  21. 21.
    National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. 2014. Accessed 23 Aug 2016.
  22. 22.
    Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Alphs L, Turkoz I, Fu DJ. Design of the schizophrenia disease recovery evaluation and modification (DREaM) study. Biol Psychiatry. 2015;77(9 Suppl 1):202S.Google Scholar
  24. 24.
    Gopal S, Xu H, McQuarrie K, et al. Caregiver burden in schizophrenia: pooled analysis of the involvement evaluation questionnaire data for paliperidone palmitate 3-month formulation. Biol Psychiatry. 2016;79(9 Suppl 1):213S.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations